U.S. health regulator pulls up Jagsonpal Pharmaceuticals for manufacturing lapses at API plant
/
A warning letter issued by the USFDA usually identifies the violation, such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use